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d Glasgow, Aberdeen, Swaffham, and London, United KingdomWhat is already known about this topic? A patient’s inspiratory flow together with the internal resistance of a dry powder
inhaler provides the energy to disaggregate the drug formulation and allow effective drug delivery; however, mis-
conceptions remain that inspiratory flow alone determines adequate dose delivery.
What does this article add to our knowledge? This study, using an In-Check DIAL, shows that most patients with
asthma in the United Kingdom can generate sufficient inspiratory flow to use high-resistance dry powder inhalers. In
addition, only approximately 70% achieve the recommended inspiratory flow rate to use a pressurized metered dose
inhaler correctly.
How does this study impact current management guidelines? Clinicians can be reassured that most people with
asthma can generate sufficient inspiratory flow to activate a range of dry powder inhalers, regardless of internal resistance.
Further evidence of some patients’ tendency to inhale “too fast” when using a pressurized metered dose inhaler is
provided.BACKGROUND: Patients’ peak inspiratory flow rate (PIFR)
may help clinicians select an inhaler device.
OBJECTIVE: To determine the proportion of patients with
asthma who could generate correct PIFRs at different inhaler
resistance settings.
METHODS: During a UK asthma review service, patients’ PIFR
was checked at resistance settings matching their current
preventer inhaler device, at R5 (high-resistance dry powder
inhaler [DPI]) and at R0 (low resistance, pressurized metered
dose inhaler [pMDI]). Correct PIFR (“pass”) was defined for R5aQueen Elizabeth University Hospital, Glasgow, United Kingdom
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890as 30 to 90 L/min and for R0 as 20 to 60 L/min. A logistic
regression model examined the independent predictors of
incorrect PIFR (“fail”) at R5 and R0. Asthma severity was
assessed retrospectively from treatment level.
RESULTS: A total of 994 adults (females 64.3%) were included,
of whom 90.4% currently used a preventer inhaler (71.5%
pMDI). PIFR pass rates were 93.7% at R5 compared with 70.5%
at R0 (P < .0001). All patients failing the R0 PIFR breathed in
too fast (>60 L/min), and 20% of patients currently using pMDI
failed for this reason. Independent risk factors for failing R5
were female sex, older age group, and current preventer pMDI
and for failing R0 included male sex, younger age group, current
preventer DPI, and mild versus severe asthma.
CONCLUSIONS: This study demonstrates that most patients
with asthma can achieve adequate inspiratory flow to activate
high-resistance DPIs, whereas approximately a third of patients
breathe in too fast to achieve recommended inspiratory flows for
correct pMDI use, including one-fifth of patients who currently
use a pMDI preventer.  2020 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2021;9:890-6)
Key words: Asthma; Inhaler resistance; Peak inspiratory flow
rateINTRODUCTION
Delivery of medications by inhalation is integral to the
management of patients with chronic respiratory conditions and
is preferred over systemic administration because of their rapid
onset of action, high local drug concentrations achieved in the
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DPI- Dry powder inhaler
PIFR- Peak inspiratory flow rate
pMDI- Pressurized metered dose inhalerlung, and fewer systemic side effects.1-3 The main classes of
portable inhaled delivery systems are pressurized metered dose
inhalers (pMDIs), dry powder inhalers (DPIs), and, most
recently, soft mist inhalers.2,3 To be effective, all types of inhalers
rely on correct inhaler technique and adherence to therapy;
therefore, choosing the most appropriate device to suit individual
patient needs together with clear guidance on their correct use
are key elements to successful therapeutic outcomes.3,4
Breath-actuated DPIs deliver the drug to the respiratory tract
as a result of the patient’s inhalation triggering the device.5 The
patient’s inspiratory flow together with the internal resistance of
the flow channel of the device provides the energy required to
disaggregate the drug formulation and allow effective delivery to
the lungs.5,6 Higher-resistance devices generate more turbulent
flow, thus contributing proportionately more to the energy
available for drug disaggregation, and therefore require less pa-
tient inspiratory flow to achieve adequate drug delivery.5,6
Conversely, devices with lower internal resistance provide less
manipulation of the patients’ inspiratory flow and rely more on
the patient generating higher inspiratory flows to activate the
device. This suggests that patients with impaired lung function
may benefit from using high-resistance devices.5 A minimum
peak inspiratory flow rate (PIFR) of 30 L/min is commonly
required to activate DPI devices; that is, to trigger deaggregation
and deliver the dose to the lungs.7-9 However, misconceptions
remain that inspiratory flow alone dictates adequate dose delivery
from DPIs and that some patients may not be able to generate
sufficient PIFR to activate devices with high internal
resistance.6,10
An estimation of a patient’s PIFR may help clinicians select a
suitable inhaler device for patients with asthma. The In-Check
DIAL is a simple tool to estimate PIFR across a range of
resistances that reflect the resistances found in different inhaler
devices. The aim of this prospective service evaluation study was
to determine the proportion of patients with asthma who were
able to generate a correct PIFR at resistance settings represen-
tative of “low-” to “high-”resistance devices using the In-Check
device, and to describe the phenotypical features of these
patients.
METHODS
Study design and patient population
This was a multicenter, prospective service evaluation study in
which sequential patients were recruited during the conduct of the
UK general practice asthma review service. The reviews were
undertaken across 41 sites, conducted at each site by 1 of 10
specialist asthma nurses employed by National Services for Health
Improvement Limited, between July 1, 2019, and October 31,
2019. Eligible patients were 5 years or older with a physician
diagnosis of asthma confirmed by the presence of an asthma Read
code. Read Codes are a coded thesaurus of clinical terms that are
routinely used by clinicians in the UK National Health Service.11
Patients with chronic obstructive pulmonary disease, othersignificant respiratory disease, or cardiac conditions were excluded.
This article presents the results for adults 18 years or older.
Because data were collected during routine service evaluation,
with no randomized intervention, ethics committee approval and
patient written informed consent were not required for this study.
All data analyzed were completely anonymized.
Patient assessments
During their asthma review, each patient’s PIFR was measured
using the In-Check DIAL version G16 (Clement Clark
International, Harlow, UK). All nurses had extensive experience in
conducting asthma reviews and were trained collectively to stan-
dardize and optimize their use of the In-Check device. Inspiratory
flow measurements were made according to a standard operating
procedure at 2 or 3 resistance (R) levels:
1. The resistance corresponding to the patient’s current principal
preventer/controller inhaler device (if they used one, and if
different from options 2 and 3 below)
2. The highest resistance setting (R5)
3. The lowest resistance setting, corresponding to pMDI (R0)
At each resistance setting tested, patients were instructed to
breathe out to comfortable exhalation before performing up to 3
inhalation maneuvers. If the patient passed, this result was recorded.
A “pass” was defined as a reading with the In-Check DIAL device of
30 to 90 L/min at settings R1 to R5 or 20 to 60 L/min at R0 setting,
based on published standards9 (Table I). If the patient failed the
assessment, 2 more attempts could be made. Patients could be
taught simple technique and be given encouragement after every
effort; for pMDI: “slow and gentle,” and for DPI: “fast and hard.”
Hence, in total, each patient could do a maximum of 9 inhalation
maneuvers.
Additional data items collected at asthma review or from patient
medical records were age, sex, body mass index, smoking status,
current principal preventer inhaler device, current principal reliever
inhaler device, symptom score/control status, number of courses of
oral corticosteroids in last 12 months, and peak expiratory flow.
Asthma severity was assessed retrospectively from the level of treat-
ment required to control symptoms and exacerbations, determined
after the patient had been on controller treatment for at least 3
months, and defined as mild asthma (well controlled with as-needed
inhaled short-acting beta-agonists or low-dose inhaled corticoste-
roids; Read code: 663V1); moderate asthma (well controlled with
low-dose inhaled corticosteroid/long-acting beta2-agonist; Read
code: 663V2); severe asthma (required moderate or high-dose
inhaled corticosteroid/long-acting beta2-agonist  add-on therapy
to maintain asthma control or remained uncontrolled despite this
treatment; Read code: 663V3).
Statistical analysis
The sample size for this study was based on a convenience sample,
with the aim of 1000 sequential patients completing the study
assessments.
The proportion of patients able to achieve a correct PIFR (pass) at
each resistance setting was described. Summary statistics (number
[%] for categorical factors and mean  SD for continuous factors)
were produced for patient demographic and clinical characteristics
and were used to describe the phenotypical features of those patients
achieving a PIFR pass or fail.
The c2 test was used to examine associations between pass rate at
different resistance settings and each categorical demographic/clinical




























Missing, n ¼ 6
Currently using preventer
Preventer inhaler device resistance: 899 (90.4)
pMDI: R0 643 (71.5)
DPI: R1 (Low) 0
R2 (Medium low) 57 (6.3)
R3 (Medium) 130 (14.5)
R4 (Medium high) 44 (4.9)
R5 (High) 25 (2.8)
BMI, Body mass index.
Data presented as n (%).




In-Check DIAL G16 flow
rate denoting clinically
effective range




NEXThaler Medium high 30-90 L/min
Twisthaler Medium high 30-90 L/min
Easyhaler
(combination)
Medium high 30-90 L/min
Turbohaler
(Pulmicort)




Clickhaler Medium 30-90 L/min
Spiromax Medium 30-90 L/min
GenuAir Medium 30-90 L/min
Ellipta Medium low 30-90 L/min
Diskhaler Medium low 30-90 L/min
Accuhaler Medium low 30-90 L/min
Breezhaler Low 30-90 L/min
Respimat pMDI/none 20-60 L/min
pMDI pMDI/none 20-60 L/min
*Comprises 5 representations of DPI device resistance (R5, High; R4, Medium high;
R3, Medium; R2, Medium low; R1, Low) and pMDI (R0).
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a logistic regression model with forward conditional approach was
used to identify statistically significant independent predictors of
PIFR fail at each of R5 and R0. Hence, factors that did not statis-
tically significantly predict failure do not appear in the final logistic
model. For each independent predictor, a reference or base group
was defined to enable interpretation of the risk of failure at R5 or R0
for each of the other levels (eg, using males as the reference group,
the odds of failure at R5 for females can be interpreted as compared
with that for males). The small number of patients who had missing
values for 1 or more of the potential predictors were excluded from
each logistic model in turn. Associations of predictors with failure
rate were presented as odds ratio and associated 95% CIs. Boxplots
illustrating median (interquartile range) peak inspiratory flow at R5
and R0 using the last value of up to 3 inhalations and stratified
across current preventer resistance groups were produced. All ana-
lyses were carried out using IBM SPSS Statistics for Windows
version 25 (IBM Corp, Armonk, NY). Statistically significant results
were defined as P values less than or equal to .05.RESULTS
Patient population
A total of 1066 patients with asthma attending a routine
asthma review service were evaluated, most of whom were adults
(n ¼ 994 [93.2%]) with 72 children (aged 17 years). This
report will focus on the 994 adults only.
Approximately two-third of the population comprised
females, 56.6% were aged between 40 and 69 years, with
26.8% older than 70 years, most patients were eitherex-smokers or never smokers (89.3%), and 75.5% were clas-
sified as overweight or obese (Table II). Most patients were
categorized as having either mild (46.4%) or moderate
(47.1%) asthma, and 90.4% were currently being prescribed
an asthma preventer therapy, most frequently administered via
a pMDI (71.5%).
PIFR pass rates
Of the whole adult study population of 994 patients, 931
patients (93.7%) achieved a PIFR pass at resistance R5, the
highest DPI resistance setting. Patients who failed to achieve a
pass rate at this resistance were more likely to be female, of older
age, and be a never smoker (Table III). Patients currently using a
pMDI (n ¼ 643) were less likely to achieve a pass with R5
(91.6%) compared with those 256 patients currently using a DPI
(98.7%).
TABLE III. Pass rates at R5 resistance by demographic
characteristics
Characteristic Pass rate, n (%) P value*
Total sample (n ¼ 994) 931 (93.7)
Sex
Female 589 (92.2)
Male 342 (96.3) .010
Age group (y)










Missing, n ¼ 2
Smoking status .037
Current smoker 103 (97.2)
Ex-smoker 291 (94.8)
Never smoked 537 (92.4)




Missing, n ¼ 48




Missing, n ¼ 6
Current preventer resistance .002
No current preventer 89 (93.7)
R0/pMDI 589 (91.6)
R2 (Medium low) 57 (100)
R3 (Medium) 129 (99.2)
R4 (Medium high) 42 (95.5)
R5 (High) 25 (100)
BMI, Body mass index; OCS, oral corticosteroid.
*Across categories from c2 linear trend test.
TABLE IV. Pass rates at R0 resistance by demographic
characteristics
Characteristic Pass rate, n (%) P value*




Missing, n ¼ 3












Missing, n ¼ 5
Smoking status (adults) .218
Current smoker 67 (63.8)
Ex-smoker 219 (71.6)
Never smoked 415 (71.6)




Missing, n ¼ 51




Missing, n ¼ 9
Current preventer resistance <.001
No current preventer 72 (75.8)
R0/pMDI 516 (80.2)
R2 (Medium low) 25 (44.6)
R3 (Medium) 67 (51.5)
R4 (Medium high) 15 (35.7)
R5 (High) 6 (24.0)
Missing, n ¼ 3
BMI, Body mass index; OCS, oral corticosteroid.
*Across categories from c2 linear trend test.
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achieving a pass rate at the R0 (pMDI) setting was 701 (70.5%),
statistically significantly fewer than those achieving a pass rate at
R5 (P < .0001) (Table IV). The reason for all patients failing the
R0 test was their PIFR being more than 60 L/min. Patients
failing to achieve a pass rate at R0 were more likely to be male
and to be using a higher-resistance preventer. Patients currently
using a pMDI (n ¼ 643) were more likely to achieve a pass at R0
(80.2%) compared with those currently using a DPI (n ¼ 256
[38.9%]). With respect to their current inhaler, only 4 of 256
patients (1.2%) currently using a DPI failed at the same
resistance as their current device. Pass rates by current deviceresistance were 100% (n ¼ 25 of 25) for R5, 100% (n ¼ 44 of
44) for R4, 98.5% (128 of 130) for R3, and 96.5% (n ¼ 55 of
57) for R2. No patients had a current device with R1 resistance.
In comparison, 19.8% of patients who currently used a pMDI
(n ¼ 643) failed to achieve a pass rate at R0 resistance.
Independent predictors of PIFR failure rates
A forward conditional logistic regression model showed that
the independent risk factors of PIFR measurement failure at
resistance R5 were sex, age group, and resistance of current
preventer (Table V). Females were 2.5 times more at risk of
TABLE V. Independent demographic and clinical predictors of
failure rate at R5 and R0 resistance
Demographic and clinical
characteristic








Female 0.59 (0.43-0.81) 2.46 (1.27-4.76)
Age group (y)
39 Reference Reference
40-54 0.91 (0.55-1.49) 1.79 (0.45-7.09)
55-69 0.55 (0.35-0.87) 3.25 (0.94-11.22)
70 0.71 (0.44-1.14) 6.12 (1.81-20.77)
Current preventer
resistance
No current preventer 1.10 (0.64-1.89) 0.82 (0.31-2.14)
R0/pMDI Reference Reference
R2 (Medium low) 5.46 (2.85-10.45) —
R3 (Medium) 5.27 (3.29-8.43) 0.08 (0.01-0.59)
R4 (Medium high) 8.85 (4.37-17.93) 0.50 (0.12-2.16)
R5 (High) 12.93 (4.78-34.92) —










BMI, Body mass index; OCS, oral corticosteroid.
Factors considered for entry into each logistic model were sex, age group, BMI
group, smoking status, severity of asthma severity, number of courses of OCS in past
12 mo, and current preventer resistance. A forward stepwise procedure was used to
identify independent predictors of failure; factors that did not independently predict
failure are excluded from the model estimates shown.
No patients with an R2 medium low or an R5 high preventer failed at R5 resistance.
*A total of 59 patients were excluded from the failure rate at the R5 model and 56
from the R0 model because of missing values for 1 or more of the 7 potential
predictors.
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and patients 40 years or older were more at risk of failing
versus those 39 years or younger, with statistically significantly
reduced odds shown in patients 70 years or older whose risk of
failing was 6 times greater than of patients 39 years or younger
(odds ratio, 6.12; 95% CI, 1.81-20.77). Compared with
patients who currently used a pMDI, patients currently using a
medium-resistance DPI (R3) had significantly reduced
odds for failing the R5 measurement (odds ratio, 0.08; 95% CI,
0.01-0.59).
The logistic regression model evaluating independent pre-
dictors of failure at R0 showed that females had significantly
reduced odds of failure compared with males (odds ratio, 0.59;
95% CI, 0.43-0.81), and patients 40 years or older were less at
risk of failing versus those 39 years or younger, the difference
being statistically significant in patients aged 55 to 69 years (odds
ratio, 0.55; 95% CI, 0.35-0.87) (Table V). Patients with severe
asthma were significantly less likely to fail than those with mild
asthma (odds ratio, 0.21; 95% CI, 0.09-0.51). Compared withpatients who currently used a pMDI, patients using a R2 pre-
venter had more than 5 times the odds (odds ratio, 5.46; 95%
CI, 2.85-10.45) of failing the R0 measurement, which increased
to 12 times the risk of failing among those currently using an R5
inhaler (odds ratio, 12.93; 95% CI, 4.78-34.92).
Figure 1 shows the distribution of peak inspiratory flow at R5
and R0 resistance across different current preventer inhalers.
Within each preventer group, there was a wide range of values.
Against R0 resistance, patients currently using DPIs fared worse
than those currently using a pMDI, with a trend toward higher
PIFR with increasing resistance in their current inhaler. Against
R5 resistance there was a more homogeneous outcome regardless
of current inhaler.DISCUSSION
This study showed that, irrespective of their current device
and with the same level of training as given at a regular asthma
review service, most patients with asthma had the capacity to
achieve the PIFR required to use a high-resistance DPI (R5), and
nearly all patients met the PIFR requirements for their current
DPI device. In comparison, approximately 30% of the total adult
patient population evaluated failed to achieve a PIFR pass rate
with the pMDI device (R0). In all patients failing the R0 test, a
PIFR greater than 60 L/min was generated; that is, they were
inhaling too fast. Of these failures, roughly 60% were current
DPI users and 40% were current pMDI users. However, nearly
20% of patients who currently used a pMDI device failed with
R0 even following 3 attempts with coaching.
The factors required to achieve correct inhaler use are well
recognized and rely on appropriate training and reinforce-
ment.12,13 These include correct preparation/handling of the
device, a gentle full exhalation away from the mouthpiece before
inhaling, ensuring a good mouth seal around the mouthpiece, a
correct inhalation maneuver (“deep and forceful from the start”
for DPI and “slow and steady over 4-5 seconds” for pMDI)
followed by a breath hold for at least 5 seconds.12-14 Our study
examined only PIFR, with the support and guidance of nurses to
overcome technique errors. A marked observation in this study
was the number of patients failing to achieve the required PIFR
for correct pMDI use due to inhaling too fast. Rapid inhalation
with a pMDI is associated with increased oropharyngeal
deposition and suboptimal drug delivery,12,13 which has poten-
tial clinical implications. A previous study evaluating inhaler
technique and asthma control as part of the UK IMPACT
(Improving the Management of Patients Asthma and COPD
Treatment) asthma review service also reported that approxi-
mately a third of patients failed the pMDI inspiratory flow
criteria (10-50 L/min) after training and showed a statistically
significant association between pMDI misuse (inhaler technique
measurements included inspiratory flow, synchronization of
flow/actuation, and breath hold) and poor asthma control.15
Giraud and Roche,16 in a general practitioner study, similarly
reported that 34% of adult patients failed the “slow inspiratory
flow” criterion and found an association between pMDI misuse
(combined criteria) and asthma instability. The CRITIKAL
(CRITical Inhaler mistaKes and Asthma controL) study, based
on an asthma review service in Australia and 7 European coun-
tries including the United Kingdom, reported that errors related
to inspiratory effort were one of the most common errors made
by patients using the Turbohaler (32%), Diskus (38%), and
FIGURE 1. Boxplot of peak inspiratory flow by current preventer resistance at (A) R0 and (B) R5. Horizontal bar of each box indicates
median, whereas upper and lower edges of each box represent the upper quartile and lower quartile, respectively. The T-bar extends to 1.5
times the height of the box. An asterisk represents extreme outliers, which are values that are more than 3 times the height of the box.
Pass rates for R5 were defined as 30 to 90 L/min and for R0 as 20 to 60 L/min, shown as dashed lines on each figure. Med, Medium.
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tested was associated with uncontrolled asthma in a multivariate
model with other inhaler errors. Although “inspiratory effort not
slow and deep” was not associated with uncontrolled asthma for
pMDI users, other specific pMDI inhaler errors were. In our
study, even patients familiar with the pMDI device failed the R0
test, illustrating the difficulties patients have with information
retention with regard to inhaler device technique. Our data
reinforce the importance of inhaler technique training with
regular and repeated checks, including clear messaging with
respect to the inhalation maneuver (DPI: Inhale quick and deep;
pMDI: Inhale slow and steady). A recent review of inhaler
technique critical errors in the context of asthma management
reported that approximately 50% of patients fail to maintaincorrect inhaler technique over time and drew attention to the
importance of patient psychosocial factors, such as motivation,
for learning and maintaining good inhaler skills.18
Only 6% of all patients tested failed the R5 measurement. In
this small number, the most significant independent risk factors
for failing the test were female sex and age 70 years or more.
Increasing age and female sex are 2 factors that have consistently
been shown to be correlated with decreased PIFRs in patients
with obstructive airway disease.7,19,20 The reasons for these
findings have not been fully established, but others suggest they
may include physiological factors such as reduced inspiratory
muscle force.19,20 In this study, asthma severity was not signifi-
cantly associated with the ability to pass at R5, also consistent
with studies that have shown no correlation between PIFR and
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7,19,20 Patient characteristics significantly associated with
the risk of failing the R0 measurement were male sex and having
mild versus severe asthma, and a trend was also observed in
younger patients failing versus older patients but this was not
consistently shown across age groups. Although the reasons for
this are not fully clear, one explanation may be that milder
severity and younger patients with asthma more easily “over-
breathe” (breath in too fast) compared with older patients and
those with more severe disease. The patient’s current preventer
device had a significant influence on pass rates for both the R5
and R0 test, indicating that those used to using a pMDI were
more likely to fail at R5 and those familiar with a DPI device
were more likely to fail at R0, the latter being consistently shown
across resistances R2 to R5, with the odds of failure increasing
with increased device resistance. These findings suggest that a
patient’s inhalation maneuver is learned or imprinted on the
basis of the device they are familiar with using. Certainly, others
have suggested that past experience with inhalers is important in
terms of maintaining correct inhaler technique and disease
control.18,21-23 This further endorses the message that regular
checks of inhaler technique and effective communication be-
tween health care providers and patients are an important part of
asthma management. Training patients to perform correct
inhalation maneuvers leading to activation of their device and
optimal drug delivery requires health care providers to know the
techniques required for each device.24 When selecting a suitable
inhaler device for patients, it is also important that health care
providers understand the concept that inhalation flow together
with the resistance of the DPI provides the energy to cause drug
deagglomeration and delivery of the whole dose to the lungs.24
Training aids such as the In-Check DIAL can aid suitable
device selection.
A strength of this study is that we evaluated a real-world
asthma population, with few exclusion criteria constraints, and
therefore these findings would be expected to be largely
generalizable. In this study, we did not evaluate how the inhaler
resistance itself affected PIFR (by comparing PIFRs across
different device resistances) but we have identified this as an area
of future interest.
CONCLUSIONS
This study demonstrates in this adult asthma population that
most patients can achieve adequate inspiratory flow to activate
high-resistance DPIs (R5), suggesting that very few patients
would be unable to use these devices. Nearly a third of patients
fail to generate an inspiratory flow for correct pMDI use due to
breathing in too fast, including a fifth of patients currently using
a pMDI.
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